1992 Volume 40 Issue Supplement4 Pages 377-389
Cefclidin (CFCL) is a new cephalosporin antibiotic, which possesses potent antipseudomonal activity. We performed laboratory and clinical studies on the drug to evaluate its usefulness in respiratory tract infections. The antibacterial activity of CFCL against respiratory pathogenic bacteria was high: its MIC50 (the minimum concentration at which 50% of isolate were inhibited) of CFCL at 106 cfu/ml was 0.2μg/ml against Haemophilus influenzae, 0.2μg/ml against Streptococcus pneumoniae, 1.56μg/ml against Branhamella catarrhalis, 0.1μg/ml against Klebsiella pneumoniae, 25μg/ml against Staphylococcus aureus, and 1.56μg/ml against Pseudomonas aeruginosa. Antipseudomonal activity was superior to those of other β-lactam antibiotics and antimicrobial agents.
The maximal sputum levels of CFCL ranged 0.52μg/ml to 2.9μg/ml in 3 patients with respiratory tract infections and the ratios of maximal sputum levels to peak serum levels were 0.8%, 1.1%, and 4.3% in 3 patients during treatment of CFCL.
Thirty-three patients with respiratory infections were studied for clinical evaluation of CFCL, which were administered 2000mg or 4000mg of CFCL daily for 6 to 19 days. Causative organisms were H.influenzae (7), S.pneumoniae (8), B.catarrhalis (6), K.Pneumoniae (2), S.aureus (1), Pseudomonas fluorescens (1) and P. aeruginosa (11). The bacteriological effect was 88.9%, and the clinical therapeutic efficacy was 90.9%.
From these results, we concluded that CFCL was an effective and useful antibiotic for the treatment of respiratory tract infections.
